Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm00255a008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic modifications for enhanced antibiotic production in rifamycin derivative-producing S699 strains: focusing on and genes.
Front Antibiot
June 2024
Institute of Pharmaceutical Biology and Biotechnology, Albert-Ludwigs-Universität, Freiburg, Germany.
Rifamycin and its derivatives are natural products that belong to the class of antibiotic-active polyketides and have significant therapeutic relevance within the therapy scheme of tuberculosis, a worldwide infectious disease caused by . Improving the oral bioavailability of rifamycin B was achieved through semisynthetic modifications, leading to clinically effective derivatives such as rifampicin. Genetic manipulation of the rifamycin polyketide synthase gene cluster responsible for the production of rifamycin B in the strain S699 represents a promising tool to generate new rifamycins.
View Article and Find Full Text PDFTargeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives.
Arch Microbiol
January 2025
Clinical Microbiology and PK-PD Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, J&K, 190005, India.
Tuberculosis (TB) remains a major global threat, with 10 million new cases and 1.5 million deaths each year. In multidrug-resistant tuberculosis (MDR-TB), resistance is most commonly observed against isoniazid (INH) and rifampicin (RIF), the two frontline drugs.
View Article and Find Full Text PDFFunctionalized Microsphere Platform Combining Nutrient Restriction and Combination Therapy to Combat Bacterial Infections.
ACS Appl Mater Interfaces
January 2025
Animal-Derived Food Safety Innovation Team, College of Veterinary Medicine, Anhui Agricultural University, Hefei 230036, China.
The escalating prevalence of multidrug-resistant (MDR) bacterial infections has emerged as a critical global health crisis, undermining the efficacy of conventional antibiotic therapies. This pressing challenge necessitates the development of innovative strategies to combat MDR pathogens. Advances in multifunctional drug delivery systems offer promising solutions to reduce or eradicate MDR bacteria.
View Article and Find Full Text PDFClinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol.
BMJ Open
December 2024
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Central, Uganda.
Introduction: Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3HP) pharmacokinetics, pharmacogenomics and their relation with ADRs.
View Article and Find Full Text PDFActinomycetes: A Source of Anticancer Metabolites.
Curr Med Chem
December 2024
Division of Microbiology, Entomology Research Institute, Loyola College, Chennai-600034, Tamil Nadu, India.
Microbes in general, actinomycetes in particular, produce a wide range of antibiotics with various biological activities such as anticancer, antimicrobial, anti-inflammatory, antituberculosis and enzyme inhibition. Actinomycetes are filamentous gram-positive bacteria found in both terrestrial and marine environments. Currently, antibiotics such as Rifamycin, Tetracycline, Kanamycin, Neomycin, Streptomycin and Clavulanic acid derived from actinobacteria are highly useful in the medical field.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!